Drugs & Pharmaceuticals

Do children under five years old need COVID-19 vaccines? Answering that question should be a simple matter of comparing the risk of infection to the risks and benefits of vaccination in this age group.
“Mitigation of the observed risks of myocarditis/pericarditis and associated uncertainties will be accomplished through labeling (including warning statements about the risks of vaccine-associated myocarditis/pericarditis) and
I recently wrote an article comparing the availability and use of the two newly approved anti-COVID drugs (1) Paxlovid and molnupiravir. Bottom line: Doctors and patients voted with their scripts.
Here we go again. Entasis Therapeutics has been struggling in the public marketplace.
Just for laughs (and what could possibly be more fun than this?), I called a bunch of local pharmacies to see whether any of them had a supply of the two newly-approved (1) antiviral COVID medications.
The good news? There's a very effective antiviral drug called Paxlovid that will keep you alive and out of the hospital when/if omicron gets you, and a second drug, molnupiravir, which doesn't work as well, but can still be helpful. The bad news?
Following the FDA's granting of Emergency Use Authorization to Merck's molnupiravir and Pfizer's Paxlovid, the only two approved direct-acting antiviral drugs; we now have two badly needed tools to deal with COVID, especially since it is
Today, NBC News managed to spoil the coming-out party of a desperately needed, lifesaving drug with its lead headline of the morning: "Pfizer antiviral pills may be risky with other medications."
It's not totally absurd to compare our war against COVID with a boxing match. The virus clearly won Round 1; aside from masks and isolation, we were pretty much defenseless.
ACSH relies on donors like you. If you enjoy our work, please contribute.

Make your tax-deductible gift today!

 

 

Popular articles